Dorian HASSOUN

Physiology
Respiratory Medicine

Severe asthme pathophysiology (eosinophils and bronchial smooth muscle)

As part of a double course in medicine and science (Inserm School), my research focused on the pathophysiology of severe asthma and its management in everyday practice. I obtained my MD in 2019 becoming qualified in respiratory medicine and then prepared a PhD studying the role of Rac-GTPase-dependent signaling pathway in severe asthma. My work relied on the NARACAS study (NCT03325088) which aimed to determine the expression and activity of Rac within smooth muscle cells in asthmatics. After the defense of my PhD in 2022, I took a fellow position in physiology within Nantes university hospital. I am in charge of the pulmonary function test department and the teaching of respiratory physiology in my university. As an early career scientist and physician, I am willing to develop innovative research into the evaluation of respiratory function, particularly in the context of bronchial and bronchiolar diseases. I am also carrying out fundamental research into severe asthma within an academic research unit (Inserm UMR 1087 / CNRS UMR 6291, l’institut du thorax), focusing on bronchial smooth muscle and eosinophils (team 3 “Vascular and pulmonary diseases”). I am also a member of the European Respiratory Society and of the French-speaking Respiratory Society (SPLF) since 2019.

EDUCATION
 

2022 PhD in Physiology, Physiopathology, Medical Systems Biology (Nantes university)

“New therapeutic strategies in severe asthma: inhibition of the Rac GTPase-dependent signaling pathway.”

2019 MD in Respiratory Medicine (Nantes university)

“Snapshot of severe asthma management in 2018-Experience at Nantes University Hospital”

“Mepolizumab in severe eosinophilic asthma in routine clinical practice”

2012 Master degree in Biology, Biotechnology and Therapeutic Research Specialization, Nantes University

PUBLICATIONS

Hassoun D., Rose L., Blanx F.-X., Magnan A., Loirand G., Sauzeau V. Bronchial smooth muscle cell in asthma: where does it fit? BMJ Open Respir Res. 2022 Sep;9(1):e001351.
Hassoun D., Loirand G., Sauzeau V. Un nouvel acteur physiopathologique dans l’asthme sévère : la GTPase Rac. Rev Mal Respir. 2022 Feb;39(2):100-103.
Hassoun D, Malard O, Barbarot S, Magnan A, Colas L. Type 2 immunity-driven diseases: Towards a multidisciplinary approach. Clin Exp Allergy. 2021 Dec;51(12):1538-1552. doi: 10.1111/cea.14029.
Dilasser F, Rose L, Hassoun D, Klein M, Rousselle M, Brosseau C, Guignabert C, Taille C, Dombret MC, Di Candia L, Heddebaut N, Bouchaud G, Pretolani M, Magnan A, Loirand G, Sauzeau V. Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. Thorax. 2021 Apr;76(4):326-334.
Colas L, Hassoun D, Magnan A. Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments. Front Med (Lausanne) 2020; 7: 98.
Braza F, Dirou S, Forest V, Sauzeau V, Hassoun D, Chesne J, Cheminant-Muller MA, Sagan C, Magnan A, Lemarchand P. Mesenchymal Stem Cells Induce Suppressive Macrophages Through Phagocytosis in a Mouse Model of Asthma. Stem Cells 2016; 34: 1836-1845.
Bouchaud G, Braza F, Chesne J, Lair D, Chen KW, Rolland-Debord C, Hassoun D, Roussey-Bihouee T, Cheminant MA, Brouard S, Bodinier M, Vrtala S, Magnan A. Prevention of allergic asthma through Der p 2 peptide vaccination. J Allergy Clin Immunol 2015; 136: 197-200 e191.
Rolland-Debord C, Lair D, Roussey-Bihouee T, Hassoun D, Evrard J, Cheminant MA, Chesne J, Braza F, Mahay G, Portero V, Sagan C, Pitard B, Magnan A. Block copolymer/DNA vaccination induces a strong allergen-specific local response in a mouse model of house dust mite asthma. PLoS One 2014; 9: e85976.
Botturi K, Langelot M, Lair D, Pipet A, Pain M, Chesne J, Hassoun D, Lacoeuille Y, Cavailles A, Magnan A. Preventing asthma exacerbations: what are the targets? Pharmacol Ther 2011; 131: 114-129.